文献速递腹部MR

基于MRI的质子密度脂肪分数联合脂肪组织识别代谢功能障碍相关脂肪性肝炎

MRI-based proton density fat fraction combined with adipose tissue for identifying metabolic dysfunction-associated steatohepatitis
RSS 订阅 · PubMed 顶刊 · 腹部影像 · 2026-10-30

本研究回顾性纳入197例经肝活检的MASLD患者,构建结合MRI-PDFF与总脂肪组织指数的MR-PAT模型识别MASH,AUC为0.866,Bootstrap内部验证AUC为0.870,诊断性能显著优于所有已建立的非侵入性检测(均p<0.05)。

要点

  • MRI-PDFF与总脂肪组织指数(TATI)是MASH的独立危险因素,可联合建模。
  • MR-PAT模型识别MASH的AUC达0.866,内部验证AUC为0.870。
  • MR-PAT模型诊断性能显著优于所有对照的非侵入性检测(均p<0.05)。

核心结论

  • MR-PAT模型联合MRI衍生的PDFF与TATI,为识别MASH提供了准确且稳健的非侵入性工具。
  • 该模型性能优于广泛认可的非侵入性检测,有望用于MASLD患者的风险分层。

研究设计与样本

  • 回顾性纳入197例连续MASLD患者,均接受肝活检、MRI-PDFF及瞬时弹性成像(TE)。
  • 采用单因素及多因素logistic回归筛选MASH独立预测因子,构建联合模型。
  • 通过1000次Bootstrap重采样进行内部验证,并与已建立的非侵入性检测比较诊断性能。

诊断标准与关键数值

  • MR-PAT模型识别MASH的AUC为0.866,Bootstrap内部验证AUC为0.870。
  • PDFF与TATI为MASH的独立危险因素(多因素logistic回归)。
  • MR-PAT模型诊断性能显著优于所有已建立的非侵入性检测(均p<0.05)。

临床应用与阅片要点

  • 在MASLD患者中可结合MRI-PDFF与脂肪组织定量(TATI)评估MASH风险。
  • MR-PAT模型可作为非侵入性风险分层工具,辅助临床决策。
  • 模型性能在临床相关亚组中保持一致,但需注意外部验证尚未进行。

局限性

  • 研究为回顾性设计,存在回顾性研究固有局限。
  • 仅进行内部Bootstrap验证,缺乏外部独立验证。
英文原文(摘要)· 点击展开

Insights Imaging . 2026 Oct 29;17(1):268. doi: 10.1186/s13244-026-02444-9. ABSTRACT OBJECTIVES: To develop a non-invasive diagnostic model combining magnetic resonance imaging (MRI)-derived proton density fat fraction (PDFF) and adipose tissue for identifying metabolic dysfunction-associated steatohepatitis (MASH). MATERIALS AND METHODS: A total of 197 consecutive patients with metabolic dysfunction-associated steatotic liver disease (MASLD) who underwent liver biopsy, MRI-PDFF, and transient elastography (TE) were retrospectively enrolled. Independent predictors of MASH were identified using univariate and multivariate logistic regression analyses. A combined model was constructed and internally validated via 1000 bootstrap resamples. The diagnostic performance was compared with that of established non-invasive tests (NITs). RESULTS: Multivariable logistic regression analyses demonstrated that the PDFF and total adipose tissue index (TATI) were independent risk factors for MASH. The MRI-based PDFF-adipose tissue (MR-PAT) model achieved an area under the receiver operating characteristic curve (AUC) of 0.866 for MASH identification. Bootstrap internal validation yielded an AUC of 0.870. The performance of the models was consistent across clinically relevant subgroups. The diagnostic performance of the MR-PAT model for MASH identification was significantly better than that of all the established NITs (all p < 0.05). CONCLUSION: The MR-PAT model, combining MRI-derived PDFF and TATI, provides an accurate and robust non-invasive tool for identifying MASH. It outperforms widely recognized NITs and holds promise for risk stratification in patients with MASLD. KEY POINTS: Question MASH is a critical histological endpoint of MASLD, but reliable non-invasive tools for its assessment remain inadequate. Findings The MR-PAT model integrating MRI-based PDFF and adipose tissue quantification demonstrates robust and excellent diagnostic performance for identifying MASH. Critical Relevance Statement The MR-PAT model leverages hepatic steatosis and the adipose tissue burden to elucidate the pathophysiological mechanisms driving steatohepatitis. It can serve as an accurate, non-invasive tool for identifying MASH and holds promise for risk stratification in patients with MASLD. PMID: 42957938 | PMC: PMC13719947 | DOI: 10.1186/s13244-026-02444-9

来源:PubMed 顶刊 · 腹部影像,查看原文。版权归原作者所有。

引用

  1. PubMed 顶刊 · 腹部影像:MRI-based proton density fat fraction combined with adipose tissue for identifying metabolic dysfunction-associated steatohepatitis

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。